At RemHealth, we help patients choose obstructive sleep apnea (OSA) treatments that are effective, practical, and sustainable over time. For many patients, that means carefully comparing invasive implant-based therapies with established non-invasive options such as CPAP and oral appliance therapy.
At this time, for many of our established patients, we generally recommend starting with conservative therapies such as CPAP or oral appliance therapy rather than moving directly to currently available hypoglossal nerve stimulation systems (HGNS). In our view, these non-invasive options often provide a more established and manageable path while the implant landscape continues to rapidly evolve.
Why We Take This Approach
Hypoglossal nerve stimulation can be an appropriate treatment for selected patients. However, implant-based therapy also involves a screening endoscopy, surgery, device programming, and ongoing in-person follow-up visits. Because of that, we believe it is reasonable for many patients to first consider therapies that are already well established, non-invasive, and available now.
We also believe the HGNS category may change meaningfully over the next year. Newer systems, such as those by LivaNova, currently in development and slated for release in 2027 may offer important advantages compared with some devices available today.
Potential Future Advantages of Newer HGNS Systems
As next-generation HGNS devices continue to develop, they may offer benefits for some patients. Depending on how these technologies ultimately reach routine clinical practice, potential advantages could include:
Broader MRI Compatibility
One possible advantage of future systems is expanded MRI access. Some next-generation devices are being designed for broader MRI compatibility, which could be important for patients who may need MRI imaging in the future.
Less Burdensome Screening
Some newer systems may reduce the need for restrictive pre-implant screening. If these technologies reach routine practice as currently described, some patients may be able to avoid additional screening procedures such as drug-induced sleep endoscopy (DISE) that are required today.
More Flexible Device Management
Future devices may also allow more convenient programming and adjustment. Remote physician management could make long-term titration and follow-up easier and may reduce the need for many in-office visits to adjust the device settings.
Longer-Term Battery Design
Some next-generation platforms are being designed with long-lasting rechargeable battery technology. If those designs perform as intended in real-world practice, they could reduce the likelihood of surgical replacement procedures over time.
What This Means for Patients Right Now
For many established patients, our current recommendation is to move forward with CPAP or oral appliance therapy rather than proceed immediately to an implant-based therapy. This is not because HGNS can never be appropriate. Rather, it reflects our view that non-invasive therapies remain the most established and practical option for many patients while newer implant technologies continue to mature.
We are also careful not to overstate future device capabilities. Some of the most promising features in this category are best described as potential future benefits, not guaranteed outcomes or fixed timelines.
Our Practical Recommendation
If you are interested in HGNS, the decision should be individualized. For many of our established patients, we currently recommend treating sleep apnea with conservative therapies such as CPAP or oral appliance therapy while continuing to monitor how the next generation of HGNS systems develops over the next year. This approach may allow some patients to benefit from a more mature device landscape before making an implant decision.
Disclaimer: This information is intended for general educational purposes only and should not be considered medical advice. Treatment decisions should be made in consultation with a qualified sleep medicine clinician.
